Pfizer

Eli Lilly

Novo Nordisk

Big Pharma's Q4 Earnings: Strong Performance, Obesity Wars, and LOE Management

Pfizer's GLP-1 Weight Loss Drug Pipeline: CEO Discusses Efficacy and Convenience

Goodrx

GoodRx Partners with Pfizer for TrumpRx Discounts on Pharmaceuticals

Pfizer's Hympavzi Receives FDA Priority Review for Label Expansion

Pfizer Sees Promise in Obesity Treatment, Sets Stage for 2028 Approval

Catalyst<ul> <li>Analyst ratings for PFE show a consensus toward optimism despite limited analyst coverage.</li></ul>Risk<ul> <li>Fund flow data indicates negative trends across all order sizes, signaling investor caution or outflows.</li> <li>Recent Bearish Engulfing and Marubozu White signals suggest potential downward price pressure despite some neutral or mixed evaluations.</li></ul>

Key Factors

Pfizer (PFE) announced positive Phase 2b results for its obesity drug PF-08653944, showing a 12.3% weight loss and favorable safety profile, advancing 10 Phase 3 trials in 2026. Pfizer's HYMPAVZI received FDA Priority Review for expanded use in hemophilia A and B patients, with a potential approval by Q2 2026. Pfizer launched a TrumpRx program offering up to 85% discounts on over 30 medications, aligning with its Most Favored Nation agreement to improve drug affordability. Pfizer's Q4 2025 earnings beat estimates, with revenue of $17.56 billion and adjusted EPS of $0.69, but pre-market shares fell 4.54% due to cautious 2026 guidance.

Recent Updates

PFE News